News

Lens option can correct for surgically induced astigmatism or an inaccurate position.

Bi-sign design compensates for aberrations resulting from misalignment.

Physicians want to make sure they see each their patient frequently enough not to miss important changes in eye disease.

According to the company, more than 400 eyes of patients from 12 European countries have been fitted with the TECNIS Eyhance Toric II IOL, with surgeons surveyed noting that their patients are pleased with the results.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

Option could prove to enhance safety for both patients and staff.

According to preliminary results, intranasally delivered ST266 is a safe treatment option.

Use of such procedures increased markedly in analysis of IRIS Registry Data.

UK physician notes a full systemic work-up needed to determine source of infection.

According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Check out the latest cartoon!

More Americans have used and continue to use teleheath for mental health care. according to a recent online poll by the American Psychiatric Association.

Procedure can improve best-corrected visual acuity, enhancing quality of life for patients.

Therapeutic choices beneficial for patients may be available in 1 to 3 years.

A word from Chief Medical Editor Peter J. McDonnell, MD.

Virtual reality, home visual field testing offer new options for physicians.

ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.

Technologies offer different approaches to different scenarios.

Upsher-Smith Laboratories LLC and Rafarm SA have announced the U.S. commercial launch of moxifloxacin ophthalmic solution, USP 0.5% following a recent abbreviated new drug application (ANDA) approval by the FDA.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

A new report by George Washington University offers a snapshot of health care workers during the COVID-19 pandemic and offers recommendations to prepare for the future.

Practices can turn a moment of crisis into a win-win for all.

Intermediate/near vision improvements are achieved without compromising distance vision.

Vyluma Inc. will focus on the development and commercialization of therapies to treat ophthalmic diseases, including pediatric myopia.

Backed by a five-year, $6.4 million grant from the National Eye Institute of the National Institutes of Health, investigators from Case Western Reserve University, University Hospitals and the Jaeb Center for Health Research hope to determine which diabetic patients can successfully donate their corneas for keratoplasty (and which should not).

The company plans to start a second Phase 3 registration study, VISION-2, as it continues on path toward a New Drug Application submission to the FDA.